Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study
Status:
Completed
Trial end date:
2020-02-03
Target enrollment:
Participant gender:
Summary
The aim of this study is to acquire preliminary, pilot data over a 2-year period on the
safety and efficacy of subcutaneous denosumab versus the current CHEO standard-of-care
(intravenous zoledronic acid) for the treatment of osteoporosis in children. Both denosumab
(1.0mg/kg) and zoledronic acid (0.025mg/kg) will be given as four doses separated by a six
month interval (i.e. at baseline, 6 months, 12 months and 18 months), with follow-up to 2
years.